Cryoport Inc (CYRX)

Currency in USD
8.20
-0.55(-6.29%)
Closed·
After Hours
8.25+0.05(+0.61%)
·
CYRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
CYRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.119.48
52 wk Range
4.589.66
Key Statistics
Prev. Close
8.2
Open
9.1
Day's Range
8.11-9.48
52 wk Range
4.58-9.66
Volume
1.63M
Average Volume (3m)
661.29K
1-Year Change
5.53%
Book Value / Share
10.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CYRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.11
Upside
+47.70%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Cryoport Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Cryoport Inc Company Profile

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company’s products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions’ Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.

Cryoport Inc SWOT Analysis


Cryoport's Crossroads
Explore Cryoport's strategic position in cold chain logistics, facing growth challenges amidst a declining stock price and market capitalization of $388 million
Financial Headwinds
Delve into Cryoport's revised revenue guidance and cost-cutting measures, aiming for adjusted EBITDA profitability by 2025 despite recent downward trends
Market Dynamics
Analyst targets range from $8 to $15 per share, reflecting mixed views on Cryoport's potential in the evolving cell and gene therapy secto
Future Trajectory
Learn how new FDA approvals and cost reduction initiatives could reshape Cryoport's growth prospects, balancing against ongoing challenges in key segments
Read full SWOT analysis

Cryoport Inc Earnings Call Summary for Q2/2025

  • Q2 2025 revenue up 14% YoY to $45.5M, EPS at $2.05 vs -$0.27 forecast; stock dips 6.01% to $7.16 post-earnings
  • Service revenue grew 21%, commercial cell and gene therapy segment up 33%; gross margin improved to 47%
  • Full-year 2025 revenue guidance reaffirmed; long-term targets of 55% gross margin and 30% adjusted EBITDA margin
  • Strategic partnership with DHL and facility expansions to drive future growth; minimal impact from Sarepta revenue reduction
  • Market volatility, supply chain risks, and regulatory changes remain key challenges despite strong financial performance
Last Updated: 05/08/2025, 23:40
Read Full Transcript

Compare CYRX to Peers and Sector

Metrics to compare
CYRX
Peers
Sector
Relationship
P/E Ratio
−7.9x−4.5x−0.5x
PEG Ratio
−0.060.000.00
Price/Book
0.8x1.4x2.6x
Price / LTM Sales
1.7x2.1x3.3x
Upside (Analyst Target)
34.1%72.4%43.4%
Fair Value Upside
Unlock23.2%7.1%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.11
(+47.70% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
2.05 / -0.27
Revenue / Forecast
45.50M / 41.74M
EPS Revisions
Last 90 days

CYRX Income Statement

People Also Watch

259.61
AVAV
-1.33%
17.96
SRPT
+10.46%
9.31
AIP
-5.77%
3.770
BLDE
-2.58%
152.93
CRCL
-5.43%

FAQ

What Stock Exchange Does Cryoport Inc Trade On?

Cryoport Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cryoport Inc?

The stock symbol for Cryoport Inc is "CYRX."

What Is the Cryoport Inc Market Cap?

As of today, Cryoport Inc market cap is 411.13M.

What Is Cryoport Inc's Earnings Per Share (TTM)?

The Cryoport Inc EPS (TTM) is -1.04.

When Is the Next Cryoport Inc Earnings Date?

Cryoport Inc will release its next earnings report on 05 Nov 2025.

From a Technical Analysis Perspective, Is CYRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cryoport Inc Stock Split?

Cryoport Inc has split 2 times.

How Many Employees Does Cryoport Inc Have?

Cryoport Inc has 1098 employees.

What is the current trading status of Cryoport Inc (CYRX)?

As of 08 Aug 2025, Cryoport Inc (CYRX) is trading at a price of 8.20, with a previous close of 8.20. The stock has fluctuated within a day range of 8.11 to 9.48, while its 52-week range spans from 4.58 to 9.66.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.